• Home
  • » 
  • Reports
  • » 
  • Bioavailability Enhancement Market (Tech...

Bioavailability Enhancement Market

Bioavailability Enhancement Market (Technologies and Services) by Drug Class, BCS Classification, Bioavailability Enhancement Approach, Dosage Form and Key Geographies: Industry Trends and Global Forecasts (2nd Edition), 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Published
    November 2022

  • Pages
    270

  • View Count
    14423

  • Buy Now

Example Insights

This image highlights the context of the Bioavailability Enhancement Market report. In addition to being a time and cost intensive process, bioavailability enhancement is fraught with several challenges; considering the expertise available with specialty service providers to improve the pharmacokinetic properties of novel molecules, drug developers are actively outsourcing their requirements This image provides list of Bioavailability Enhancement Service Providers. Outsourcing has emerged as a popular model for improving drug bioavailability, with nearly 115 companies offering a wide range of services based on different bioavailability enhancement principles This image represents the market landscape of bioavailability enhancement service providers. At present, more than 80% of the players are offering bioavailability enhancement services focused on improving the drug solubility, primarily by adopting the solid dispersion approach This image provides list of Bioavailability Enhancement Technologies. Advances in bioavailability enhancement technologies have enabled the development of novel formulations with improved pharmacokinetic properties, resulting in lucrative business opportunities for technology providers
This image presents the market distribution of Bioavailability Enhancement Technologies. Over 50% of the technologies are focused on enhancing the bioavailability of small molecules, specifically those intended for delivery via the oral route This image highlights the contemporary market trends in Bioavailability Enhancement Technologies domain. Industry stakeholders are steadily expanding their existing capabilities in order to enhance their respective service portfolios and drive compliance to evolving industry benchmarks This image focuses on the recent partnerships inked between stakeholders engaged in the domain of Bioavailability Enhancement Market. A rise in partnerships focused on bioavailability enhancement services and technology platforms validate the growing interest in this domain; ~40% of such deals were instances of mergers and acquisitions This image provides information on the completed, ongoing, and planned clinical studies related to bioavailability enhancement of various drug compounds and / or candidates. In the past decade, several clinical trials have been registered for evaluating novel therapeutic interventions with improved bioavailability, across different geographical regions
This image highlights more than 5,800 peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates. 5,800+ articles discussing various bioavailability enhancement techniques have been published in different scientific journals, thereby, indicating the rapid pace of research activity within this domain This image represents the analysis of patents that have been filed / granted for bioavailability enhancement approaches and technologies. Bioavailability enhancement domain is characterized by extensive R&D activity, leading to the development of multiple high value technologies and a strong intellectual property portfolio; we identified over 9,900 such patents This image provides information on Technology Evaluation Framework along with the Key Factors Impacting the Success of Bioavailability Enhancement Technology. With the market evolving at a steady pace, emerging players need to incorporate innovative bioavailability enhancement technologies to augment their service portfolio and surpass the competition This image highlights the the current and future demand for bioavailability enhancement technologies and services. Considering the concerns related to low solubility / permeability of certain marketed drugs and a large number of NCEs, the demand for bioavailability enhancement technologies and services is anticipated to rise in the future
This image provides information on the current as well as future market scenario of bioavailability enhancement technologies and services domain. Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is likely to grow at CAGR of ~11%, till 2035 This image highlights the market segments of bioavailability enhancement technologies and services domain. The estimated market opportunity is expected to be well distributed across different types of drug classes, dosage forms and key geographical regions    

 

Report Description

Bioavailability Enhancement Market

The space of bioavailability enhancement technologies and services, driven by the increase in number of BCS II and BCS IV molecules in early phases of development, is likely reach USD 10 billion by 2035, growing at a CAGR of ~11%. Bioavailability is known to form an integral part of the drug pharmacokinetics. As a result, over the last couple of years, the concept of bioavailability has garnered significant attention in the pharmaceutical industry. Further, a study conducted on terminated drug development projects revealed that majority of the candidates fail in early phases. The study further highlighted that the aforementioned drug failures can primarily be attributed to the problems associated with pharmacokinetic profiles, ADME (distribution, metabolism, absorption and excretion) properties and toxicity-related concerns. At present, more than 40% of the marketed drugs are believed to possess low bioavailability, while around 90% of all New Chemical Entities (NCEs), which are being evaluated in pre-clinical and clinical stages of development, exhibit solubility / permeability related issues.Consequently, recent years have seen a rise in drug developers evaluating various re-formulation strategies to improve the bioavailability of existing drugs / drug candidates. In fact, an increasing number of drug candidates have been granted approval via the 505(b)(2) pathway; the aforementioned pathway is used to gain approval for novel formulations consisting of previously approved active pharmaceutical ingredient (API). Additionally, given the shifting focus of drug developers towards development of lipophilic drug compounds, the industry is actively undertaking efforts to identify various bioavailability enhancement techniques, in order to mitigate the challenge of low bioavailability and stability. 

In this context, it is also important to mention that a significant number of players engaged in the development of therapeutic interventions currently prefer to outsource their bioavailability enhancement operations to contract service providers. This trend can be attributed to the fact that service providers usually have specialized facilities and equipment, along with established processes, which can help drug developers to accomplish the desired goals in shorter timelines. In order to cater to the requirement for such services, a number of bioavailability enhancement focused service providers for API have been established in the past few years, across various regions of the globe. At present, the bioavailability enhancement service providers are actively trying to consolidate their presence in this field by entering into strategic alliances, to meet the indubitably rising demand for effective therapeutics. For this purpose, substantial mergers and acquisitions have been reported in this market, as service providers strive to become one-stop-shops, to cater to the diverse needs for their clientele. In addition, several stakeholders are engaged in the development of proprietary technologies, based on sustained release principle and bioavailability enhancers, to maintain a competitive edge in this rapidly emerging market. In fact, since 2017, close to 6,000 research articles, evaluating various bioavailability enhancement techniques have been published across several reputed journals. In addition, close to 10,000 patents have been filed, till 2022, providing a significant scientific push for the development of novel approaches. Driven by the increase in number of BCS II and BCS IV molecules being evaluated in early phases of development, the bioavailability enhancement domain is expected to grow at a steady pace in the foreseen future. 

Recent Developments in Bioavailability enhancement Market

Several recent developments have taken place in the field of bioavailability enhancement. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

 

  • In August 2023, Mountain Valley MD published Soluvec™ Trial Data in Therapeutic Delivery demonstrating significant enhancement in Ivermectin solubilization and bioavailability. 
  • In July 2023, Zeon Lifesciences launched liquid filled capsules. These capsules have capability to offer a unique delivery system enclosing a host of advantages including enhanced bioavailability and absorption rate. 
  • In May 2023, AustinPx announced the expansion of its capabilities by installing PROCEPT modular 4M8-Trix with an aim of developing spray dried amorphous solid dispersions. This will strengthen company’s portfolio of bioavailability enhancement technologies. 
     

Scope of the Report

The “Bioavailability Enhancement Technologies and Services Market (2nd Edition) by Drug Class (New Drug Approvals and Generics), BCS Classification (BCS II Drugs and BCS IV Drugs), Bioavailability Enhancement Approach (Solid Dispersion, Size Reduction, Lipid-based, and Other Approaches), Dosage Form (Liquids, Solids, Semi-Solids, and Fine Particles) and Key Geographies (North America, Europe, Asia, Latin America, Middle East and North Africa and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of the bioavailability enhancement technologies and services market. The study features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in providing bioavailability enhancement technologies and services. The table below highlights various market segmentations done in the report.

Market Segmentations

Report Attribute Details

Forecast Period

2022 – 2035

Drug Class

 New Drug Approvals, Generics

BCS Classification

 BCS II drugs, BCS IV drugs

Bioavailability Enhancement Approach

 Solid dispersion, size reduction, lipid-based

Dosage Form

 Liquids, solids, semi-solids, fine particles / powders
Key Geographical Regions North America, Europe, Asia-Pacific, MENA, Latin America and Rest of the World

 

Amongst other elements, the report features:

  • An executive summary of the insights captured in our research. It offers a high-level view on the current state of bioavailability enhancement technologies and services market and its likely evolution in the mid-long term.
  • A general introduction to bioavailability enhancement, featuring information on the historical overview of bioavailability, assessment of drug bioavailability, need for bioavailability enhancement, and general factors affecting drug bioavailability. Additionally, the chapter includes details on the various types of bioavailability enhancement approaches / technologies employed by various industry stakeholders. The chapter concludes with a discussion on the key growth drivers, as well as upcoming trends in this field.
  • A detailed assessment of the overall market landscape of bioavailability enhancement service providers, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release and others), bioavailability enhancement approach employed, including [A] solid dispersion (spray-dried dispersion, hot melt extrusion, polymers, agglomeration / granulation, lyophilization, inclusion complexes, super critical fluid, solvent evaporation and other solid dispersion approaches), [B] size reduction (conversion to nanotechnology-based formulation, high pressure homogenization / mirconization, bead layering, microfluidics, and other miscellaneous size reduction approach), [C] lipid-based (liposomes, self-emulsifying drug delivery system, excipients, micelles, lipid-nanotechnology based formulations and other lipid-based formulations), and other bioavailability enhancement approaches (co-crystallization, chemical modification, and other miscellaneous bioavailability enhancement technologies), type of dosage form supported (solids, liquids, fine particles and semi-solids), and route of administration of drug product (oral, topical, parenteral and others).
  • A detailed assessment of the current market landscape of bioavailability enhancement technology providers, featuring analysis based on several parameters, such as year of establishment, company size (in terms of employee count) and location of headquarters. In addition, the chapter highlights an in-depth analysis of various bioavailability enhancement technologies based on bioavailability enhancement principle supported (solubility enhancement, absorption enhancement, sustained release, and others), bioavailability enhancement approach employed (solid dispersion, nanotechnology, lipid-based, other size reduction, chemical modification, and others), type of molecule (small molecules and biologics), type of dosage form supported (solids, liquids, fine particles, and semi-solids), route of administration (oral, topical, parenteral, and others), availability for license and associated intellectual property rights.
  • An in-depth analysis, highlighting the contemporary market trends, using six schematic representations, including [A] a world map representation depicting the region-wise distribution of various stakeholders engaged in offering bioavailability enhancement services, on the basis of their company size, [B] a waffle chart representation, highlighting the regional distribution of bioavailability enhancement service providers, based on various types of bioavailability enhancement approaches employed by them,  [C] a heat map representation of bioavailability enhancement service providers, based on bioavailability enhancement approaches and type of dosage form, [D] a horizontally grouped bar chart, highlighting the distribution of bioavailability enhancement service providers based on their company size and type of bioavailability enhancement principles, [E] an insightful tree map representation of bioavailability enhancement service providers (in terms of bioavailability enhancement principles employed and bioavailability enhancement approaches offered),  as well as [F] a 3D bubble analysis comparing the key players engaged in this domain, based on several relevant parameters (such as year of establishment, company size, number of bioavailability enhancement approaches offered and region).
  • Elaborate profiles of various prominent players that are engaged in offering bioavailability enhancement technologies and services. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), bioavailability enhancement services portfolio, recent developments and an informed future outlook.
  • A company benchmarking analysis of various players engaged in this domain. It highlights the capabilities of industry players in terms of their expertise across various services related to bioavailability enhancement of drug compounds and / or drug candidates. The analysis allows companies to compare their existing capabilities within and beyond their peer groups and identify opportunities to gain a competitive edge in the industry.  
  • An analysis of partnerships that have been inked between several stakeholders engaged in providing bioavailability enhancement services and technologies, during the period 2013-2022, covering mergers and acquisitions, licensing agreements, alliances, product development and manufacturing agreements, research and development agreements, product development and commercialization agreements, service agreements, and other agreements.
  • A detailed review of more than 5,800 peer-reviewed, scientific articles related to research on bioavailability enhancement of drug compounds and / or drug candidates, based on parameters, such as year of publication, type of publication and popular keywords. The chapter also provides information on top journals, top publishers and top copyright holders (in terms of number of articles published)
  • An in-depth analysis of the patents that have been filed / granted for bioavailability enhancement approaches and technologies since 2003, based on important parameters, such as type of patent, patent application year, patent publication year, bioavailability enhancement approach, CPC symbols, geography, emerging focus area, type of organization, leading industry and non-industry players (in terms of number of patents filled / granted), and individual patent assignees (in terms of size of intellectual property portfolio). The chapter also includes an insightful benchmarking and valuation analysis.
  • An in-depth analysis of completed, ongoing, and planned clinical studies related to bioavailability enhancement of various drug compounds and / or candidates, based on several relevant parameters, such as trial registration year, trial phase, current recruitment status, enrolled patient population, study design, type of sponsor / collaborator, leading industry and non-industry players (in terms of number of registered trials conducted), type of molecule and key geographies.
  • An insightful framework evaluating the bioavailability enhancement approaches based on various parameters, such as number of technologies, number of approved drugs, trends highlighted in published literature and patents, and business models adopted by industry stakeholders. It also provides a value addition matrix for respective bioavailability enhancement approaches currently employed by stakeholders.
  • An elaborate analysis in order to estimate the current and future demand for bioavailability enhancement technologies and services, based on several relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs) and dosage form (liquids, solids, semi-solids, and fine particles / powders) for the period 2022-2035. Kindly note that input parameters considered for this analysis include number of New Chemical Entity (NCE) candidates and generic / reformulated drug products that are likely to undergo formulation development over the period of next 13 years.
  • A detailed market forecast analysis, highlighting the likely evolution of the bioavailability enhancement services market in the short to mid-term and long term, over the period 2022-2035. Further, the year-wise projections of the current and future opportunity have been segmented based on relevant parameters, such as drug class (new drug approvals and generics), BCS classification (BCS II drugs and BCS IV drugs), bioavailability enhancement approach (solid dispersion, size reduction, and lipid-based), dosage form (liquids, solids, semi-solids, an fine particles / powders) and key geographies (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, which represent different tracks of the industry’s growth. 

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

  • Who are the key players engaged in the bioavailability enhancement technologies and services market?
  • Which are the key geographies where bioavailability enhancement technology and service providers are located?
  • What are the recent developments and expected trends in the bioavailability enhancement industry?
  • Which partnership models are commonly adopted by stakeholders offering bioavailability enhancement solutions?
  • What is the evolving trend of publications focused on bioavailability enhancement technologies?
  • Which companies are actively filing patents to drive innovation in the bioavailability enhancement market?
  • What are the key market trends and driving factors that are likely to impact the growth of the bioavailability enhancement technologies and services market?
  • How is the current and future opportunity likely to be distributed across key market segment?

Contents

Table of Contents

1. PREFACE 
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Historical Evolution of Bioavailability Enhancement Technologies
3.3. Assessment of Drug Bioavailability
3.3.1. Key Considerations for Bioavailability and Assessment Studies
3.3.1.1. Absolute Bioavailability
3.3.1.2. Relative Bioavailability
3.3.1.3. Single and Multiple Dose Studies
3.3.2. Studies in Healthy Subjects and Patients
3.3.2.1. Different Bioavailability Assessment methods

3.4. Need for Bioavailability Enhancement
3.5. Factors Affecting Bioavailability
3.5.1. Drug Related Factors
3.5.2. Patient Physiology Related Factors

3.6. Bioavailability Enhancement Technologies
3.6.1. Physical Technologies for Bioavailability Enhancement
3.6.1.1. Solid Dispersion
3.6.1.1.1. Classification of Solid Dispersion Approaches
3.6.1.1.2. Methodologies for Solid Dispersion Approaches
3.6.1.1.2.1. Hot Melt Extrusion
3.6.1.1.2.2. Solvent Evaporation
3.6.1.1.2.3. Spray-Dried Dispersion
3.6.1.1.2.4. Other Techniques Used for Solid Dispersion

3.6.1.2. Nanosuspension Technology
3.6.1.2.1. Top-Down Approach
3.6.1.2.2. Bottom-Up Approach
  
3.6.2. Chemical Technologies for Bioavailability Enhancement
3.6.2.1. Lipid-Based Formulations
3.6.2.2. Non-Metal-Based Drug Delivery Systems
3.6.2.3. Polymer-Based Drug Delivery Systems

3.6.3. Biological Technologies for Bioavailability Enhancement
3.7. Concluding remarks

4. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT SERVICE PROVIDERS 
4.1. Chapter Overview
4.2. Bioavailability Enhancement Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Bioavailability Enhancement Principle

4.2.5. Analysis by Bioavailability Enhancement Approach
4.2.5.1. Analysis by Solid Dispersion Approaches
4.2.5.2. Analysis by Size Reduction Approaches
4.2.5.3. Analysis by Lipid-Based Approaches
4.2.5.4. Analysis by Other Bioavailability Enhancement Approaches

4.2.6. Analysis by Dosage Form
4.2.7. Analysis by Route of Administration

5. MARKET LANDSCAPE: BIOAVAILABILITY ENHANCEMENT TECHNOLOGY PROVIDERS
5.1. Chapter Overview
5.2. Bioavailability Enhancement Technologies: Technology Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Company Size and Location of Headquarters
5.2.5. Leading Players: Analysis by Number of Technologies

5.3. Bioavailability Enhancement Technologies: Market Landscape
5.3.1. Analysis by Bioavailability Enhancement Principle
5.3.2. Analysis by Bioavailability Enhancement Approach
5.3.3. Analysis by Bioavailability Enhancement Principle and Bioavailability EnhancementApproach

5.3.4. Analysis by Type of Molecule
5.3.5. Analysis by Bioavailability Enhancement Approach and Type of Molecule
5.3.6. Analysis by Dosage Form
5.3.7. Analysis by Route of Administration
5.3.8. Analysis by Availability for License
5.3.9. Analysis by Intellectual Property Rights

6. KEY INSIGHTS
6.1. Chapter Overview
6.1.1. Analysis by Company Size and Location of Headquarters (World Map Representation)
6.1.2. Analysis by Location of Headquarters and Bioavailability Enhancement Approach (Waffle Chart)
6.1.3. Analysis by Bioavailability Enhancement Approach and Dosage Form (Heatmap Representation)
6.1.4. Analysis by Company Size and Bioavailability Enhancement Principle (Horizontally Grouped Bar Chart)
6.1.5. Analysis by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach (Tree map Representation)
6.1.6. Analysis by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region (3D Bubble Chart)

7. COMPANY PROFILES
7.1. Chapter Overview
7.2. Adare Pharma Solutions
7.2.1. Company Overview
7.2.2. Recent Developments and Future Outlook

7.3. Ascendia Pharmaceuticals
7.3.1. Company Overview
7.3.2. Recent Developments and Future Outlook

7.4. Catalent 
7.4.1. Company Overview
7.4.2. Financial Overview 
7.4.3. Recent Developments and Future Outlook

7.5. Lonza 
7.5.1. Company Overview
7.5.2. Financial Overview 
7.5.3. Recent Developments and Future Outlook

7.6. Lubrizol Life Science Health
7.6.1. Company Overview
7.6.2. Recent Developments and Future Outlook

7.7. Pace Life Sciences
7.7.1. Company Overview
7.7.2. Recent Developments and Future Outlook

7.8. Quotient Sciences
7.8.1. Company Overview
7.8.2. Recent Developments and Future Outlook

7.10. WuXi STA (A Subsidiary of WuXi AppTec)
7.10.1. Company Overview
7.10.2. Financial Overview 
7.10.3. Recent Developments and Future Outlook

8. COMPANY BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Company Benchmarking Analysis: Methodology
8.3. Company Benchmarking Analysis: Peer Groups
8.3.1. Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
8.3.2. Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
8.3.3. Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
8.3.4. Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
8.3.5. Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
8.3.6. Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
8.3.7. Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
8.3.8. Benchmarking of Players based in Asia and Rest of the World, Established Post -2000 (Peer Group VIII)

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Bioavailability Enhancement: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Analysis by Type of Partnership and Type of Partner
9.3.6. Most Active Players: Analysis by Number of Partnerships

9.4. Analysis by Geography
9.4.1. Analysis by Region
9.4.2. Analysis by Country
9.4.3. Analysis by Type of Partnership and Location of Partner Headquarters

10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Bioavailability Enhancement: Publication Analysis
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Type of Publication
10.3.3. Analysis by Bioavailability Enhancement Approach 
10.3.4. Analysis by Year of Publication and Bioavailability Enhancement Approach 
10.3.5. Most Popular Journals: Analysis by Number of Publications
10.3.6. Most Popular Journals: Analysis of Journal Impact Factor
10.3.7. Most Popular Publishers: Analysis by Number of Publications
10.3.8. Most Popular Copyright Holders: Analysis by Number of Publications
10.3.9. Analysis by Popular Keywords

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Bioavailability Enhancement: Patent Analysis
11.3.1. Analysis by Application Year
11.3.2. Analysis by Publication Year
11.3.3. Analysis by Bioavailability Enhancement Approach
11.3.4. Analysis by CPC Symbols
11.3.5. Analysis by Geography
11.3.6. Analysis by Emerging Focus Areas
11.3.7. Analysis by Type of Organization
11.3.8. Leading Players: Analysis by Number of Patents

11.4. Bioavailability Enhancement Market: Patent Benchmarking Analysis
11.4.1. Analysis by Patent Characteristics

11.5. Bioavailability Enhancement Market: Patent Valuation Analysis
11.6. Leading Patents: Analysis by Number of Citations

12. CLINICAL TRIAL ANALYSIS
12.1. Chapter Overview
12.2. Guidelines To Conduct Bioavailability Studies
12.3. Bioavailability Enhancement: Clinical Trials Analysis
12.3.1. Research Methodology
12.3.2. Analysis of Trials by Trial Registration Year
12.3.3. Analysis of Enrolled Patient Population by Trial Registration Year 
12.3.4. Analysis of Trials by Study Design
12.3.5. Analysis of Trials by Trial Phase
12.3.6. Analysis of Trials by Trial Recruitment Status
12.3.7. Analysis of Trials by Type of Sponsor / Collaborator
12.3.8. Analysis by Type of Molecule and Trial Phase
12.3.9. Leading Industry Players: Analysis by Number of Registered Trials
12.3.10. Leading Non-Industry Players: Analysis by Number of Registered Trials
12.3.11. Analysis by Study Focus
12.3.12. Analysis of Trials by Geography
12.3.13. Analysis of Enrolled Patient Population by Geography

13. TECHNOLOGY EVALUATION FRAMEWORK
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Technologies based on Solid Dispersion Approaches
13.3.1 List of Approved Drugs 
13.3.2 Trends in Intellectual Capital
13.3.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers

13.4. Technologies based on Size Reduction Approaches
13.4.1 List of Approved Drugs 
13.4.2 Trends in Intellectual Property
13.4.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers

13.5. Technologies based on Lipid-based Approaches
13.5.1 List of Approved Drugs 
13.5.2 Trends in Intellectual Property
13.5.3. Trends in Research Activity
13.3.4. Business Model Adopted by Developers

13.6. Technology Evaluation Framework: Wind Rose Representation
13.7. Technology Evaluation Framework: Spider Web Representation
13.8. Results and Discussions

14. DEMAND ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035
14.4. Analysis by Drug Class, 2022 and 2035
14.4.1. Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035
14.4.2. Demand for Bioavailability Enhancement Technologies and Services forGenerics, 2022-2035

14.5. Analysis by BCS Classification, 2022 and 2035
14.5.1. Demand for Bioavailability Enhancement Technologies and Services for BCS IIDrugs, 2022-2035
14.5.2. Demand for Bioavailability Enhancement Technologies and Services for BCSIV Drugs, 2022-2035

14.6. Analysis by Dosage Form, 2022 and 2035
14.6.1. Demand for Bioavailability Enhancement Technologies and Services forLiquids, 2022-2035
14.6.2. Demand for Bioavailability Enhancement Technologies and Services for Solids,2022-2035
14.6.3. Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035
14.6.4. Demand for Bioavailability Enhancement Technologies and Services for FineParticles / Powders, 2022-2035
14.7. Concluding Remarks

15. MARKET FORECAST AND OPPURTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Forecast Methodology and Key Assumptions
15.3. Global Bioavailability Enhancement Services Market, 2022-2035

15.4. Bioavailability Enhancement Services Market: Analysis by Drug Class, 2022 and 2035
15.4.1. Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035
15.4.2. Bioavailability Enhancement Services Market for Generics, 2022-2035

15.5. Bioavailability Enhancement Services Market: Analysis by BCS Classification, 2022 and 2035
15.5.1. Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035
15.5.2. Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035

15.6. Bioavailability Enhancement Services Market: Analysis by Bioavailability Enhancement Approach, 2022 and 2035
15.6.1. Bioavailability Enhancement Services Market for Lipid Based Approaches,2022-2035
15.6.2. Bioavailability Enhancement Services Market for Solid DispersionApproaches, 2022-2035
15.6.3. Bioavailability Enhancement Services Market for Size Reduction Approaches,2022-2035
15.6.4. Bioavailability Enhancement Services Market for Other EnhancementApproaches, 2022-2035

15.7. Bioavailability Enhancement Services Market: Analysis by Dosage Form, 2022 and 2035
15.7.1. Bioavailability Enhancement Services Market for Liquids, 2022-2035
15.7.2. Bioavailability Enhancement Services Market for Solids, 2022-2035
15.7.3. Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035
15.7.4. Bioavailability Enhancement Services Market for Fine Particles / Powders,2022-2035
15.7.5. Bioavailability Enhancement Services Market for Other Dosage Forms, 2022-2035

15.8.  Bioavailability Enhancement Services Market: Analysis by Key Geographies, 2022 and 2035
15.8.1. Bioavailability Enhancement Services Market in North America, 2022-2035
15.8.2. Bioavailability Enhancement Services Market in Europe, 2022-2035
15.8.3. Bioavailability Enhancement Services Market in Asia, 2022-2035
15.8.4. Bioavailability Enhancement Services Market in Latin America, 2022-2035
15.8.5. Bioavailability Enhancement Services Market in Middle East and North Africa,2022-2035
15.8.6. Bioavailability Enhancement Services Market in Rest of the World, 2022-2035
15.9. Concluding Remarks 

16. CONCLUSION

17. APPENDIX I: LIST OF COMPANIES

18. APPENDIX II: TABULATED DATA

List of Figures

Figure 2.1 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 2.2 Executive Summary: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Publication Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Clinical Trial Analysis
Figure 2.7 Executive Summary: Demand Analysis
Figure 2.8 Executive Summary: Market Forecast
Figure 3.1 Bioavailability Enhancement Technologies: Historical Evolution of Bioavailability Enhancement Technologies
Figure 3.2 Single Dose Study: Drug Concentration-Time Curve
Figure 3.3 Multiple Dose Study: Drug Concentration-Time Curve
Figure 3.4 Different Bioavailability Assessment Methods
Figure 3.5 Biopharmaceutical Classification System
Figure 3.6 Factors Affecting Drug Bioavailability
Figure 3.7 Solid Dispersion Formulations: Classification
Figure 3.8 Solid Dispersion Formulations: Preparation Methodologies
Figure 3.9 Solid Dispersion Formulations: Melt Agglomeration Technique
Figure 3.10 Nanosuspension Formulations: Preparation Methodologies
Figure 3.11 Lipid-based Formulations: Classification
Figure 3.12 Biological Formulations: Classification
Figure 4.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Figure 4.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Figure 4.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Figure 4.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 4.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Figure 4.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Figure 4.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Figure 4.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Figure 4.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Figure 4.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Figure 4.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Figure 4.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Figure 5.1 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Figure 5.2 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Figure 5.3 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Figure 5.4 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Figure 5.5 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Figure 5.6 Leading Players: Distribution by Number of Technologies
Figure 5.7 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Figure 5.8 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Figure 5.9 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 5.10 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Figure 5.11 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Figure 5.12 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Figure 5.13 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Figure 5.14 Bioavailability Enhancement Technologies: Distribution by Availability for License
Figure 5.15 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Figure 6.1 Key Insights: Distribution by Company Size and Location of Headquarters
Figure 6.2 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Figure 6.3 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Figure 6.4 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Figure 6.5 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Figure 6.6 Key Insights: Distribution by Year of Establishment, Company Size, Number of Bioavailability Enhancement Approaches Offered and Region
Figure 7.1 Catalent: Annual Revenues, 2017-2022 (USD Billion)
Figure 7.2 Lonza: Annual Revenues, 2017-2022 H1 (CHF Billion)
Figure 7.3 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, 2017-2022 H1 (USD Billion)
Figure 8.1 Company Benchmarking Analysis: Distribution by Year of Establishment and Location of Headquarters
Figure 8.2 Benchmarking of Players based in North America, Established Pre-2000 (Peer Group I)
Figure 8.3 Benchmarking of Players based in North America, Established 2000-2010 (Peer Group II)
Figure 8.4 Benchmarking of Players based in North America, Established Post-2010 (Peer Group III)
Figure 8.5 Benchmarking of Players based in Europe, Established Pre-2000 (Peer Group IV)
Figure 8.6 Benchmarking of Players based in Europe, Established 2000-2010 (Peer Group V)
Figure 8.7 Benchmarking of Players based in Europe, Established Post-2010 (Peer Group VI)
Figure 8.8 Benchmarking of Players based in Asia and Rest of the World, Established Pre-2000 (Peer Group VII)
Figure 8.9 Benchmarking of Players based in Asia and Rest of the World, Established Post-2000 (Peer Group VIII)
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.6 Most Active Players: Distribution by Number of Partnerships
Figure 9.7 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Figure 9.8 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Figure 9.9 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Partner Headquarters
Figure 10.1 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Figure 10.2 Publication Analysis: Distribution by Type of Publication
Figure 10.3 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Figure 10.4 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Figure 10.5 Most Popular Journals: Distribution by Number of Publications
Figure 10.6 Most Popular Journals: Distribution by Journal Impact Factor
Figure 10.7 Most Popular Publishers: Distribution by Number of Publications
Figure 10.8 Most Popular Copyright Holders: Distribution by Number of Publications
Figure 10.9 Publication Analysis: Distribution by Popular Keywords
Figure 11.1 Patent Analysis: Distribution by Type of Patent
Figure 11.2 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Figure 11.3 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Figure 11.4 Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents, Pre-2010 - 2022
Figure 11.5 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Figure 11.6 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Figure 11.7 Patent Analysis: Distribution by CPC Symbols
Figure 11.8 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Figure 11.9 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Figure 11.10 Patent Analysis: Distribution by Emerging Focus Area
Figure 11.11 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Figure 11.12 Leading Industry Players: Distribution by Number of Patents
Figure 11.13 Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.14 Leading Patent Assignees: Distribution by Number of Patents
Figure 11.15 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Figure 11.16 Patent Analysis: Distribution of Patents by Age (Pre-2010 - 2022)
Figure 11.17 Bioavailability Enhancement: Patent Valuation
Figure 12.1 Clinical Trial Analysis: Scope and Methodology
Figure 12.2 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010 - 2022
Figure 12.3 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.4 Bioavailability Studies: Distribution of Trials by Study Design
Figure 12.5 Bioavailability Studies: Distribution of Trials by Trial Phase
Figure 12.6 Bioavailability Studies: Distribution of Trials by Recruitment Status
Figure 12.7 Bioavailability Studies: Distribution of Trials by Type of Sponsor / Collaborator
Figure 12.8 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Figure 12.9 Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.10 Leading Non-Industry Players: Distribution by Number of Registered Trials
Figure 12.11 Bioavailability Studies: Distribution by Study Focus
Figure 12.12 Bioavailability Studies: Geographical Distribution of Trials
Figure 12.13 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Figure 13.1 Technologies based on Lipid-based Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.2 Technologies based on Lipid-based Approaches: Trends in Research Activity (Number of Publications)
Figure 13.3 Technologies Evaluation Framework: Lipid-based Approaches
Figure 13.4 Technologies based on Size Reduction Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.5 Technologies based on Size Reduction Approaches: Trends in Research Activity (Number of Publications)
Figure 13.6 Technologies Evaluation Framework: Size Reduction Approaches
Figure 13.7 Technologies based on Solid Dispersion Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.8 Technologies based on Solid Dispersion Approaches: Trend in Research Activity (Number of Publications)
Figure 13.9 Technologies Evaluation Framework: Solid Dispersion Approaches
Figure 13.10 Technologies based on Other Approaches: Trends in Intellectual Capital (Number of Patents)
Figure 13.11 Technologies based on Other Approaches: Trends in Research Activity (Number of Publications)
Figure 13.12 Technologies Evaluation Framework: Other Approaches
Figure 13.13 Technology Evaluation Framework: Spider Web Representation
Figure 14.1 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Figure 14.2 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035
Figure 14.3 Demand for Bioavailability Enhancement Technologies and Services for New Drug Approvals, 2022-2035 (In Terms of Number of Projects)
Figure 14.4 Demand for Bioavailability Enhancement Technologies and Services for Generics, 2022-2035 (In Terms of Number of Projects)
Figure 14.5 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035
Figure 14.6 Demand for Bioavailability Enhancement Technologies and Services for BCS II Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 14.7 Demand for Bioavailability Enhancement Technologies and Services for BCS IV Drugs, 2022-2035 (In Terms of Number of Projects)
Figure 14.8 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035
Figure 14.9 Demand for Bioavailability Enhancement Technologies and Services for Liquids, 2022-2035 (In Terms of Number of Projects)
Figure 14.10 Demand for Bioavailability Enhancement Technologies and Services for Solids, 2022-2035 (In Terms of Number of Projects)
Figure 14.11 Demand for Bioavailability Enhancement Technologies and Services for Semi-Solids, 2022-2035 (In Terms of Number of Projects)
Figure 14.12 Demand for Bioavailability Enhancement Technologies and Services for Fine Particles / Powders, 2022-2035 (In Terms of Number of Projects)
Figure 15.1 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Billion)
Figure 15.2 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035
Figure 15.3 Bioavailability Enhancement Services Market for New Drug Approvals, 2022-2035 (USD Billion)
Figure 15.4 Bioavailability Enhancement Services Market for Generics, 2022-2035 (USD Billion)
Figure 15.5 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035
Figure 15.6 Bioavailability Enhancement Services Market for BCS II Drugs, 2022-2035 (USD Billion)
Figure 15.7 Bioavailability Enhancement Services Market for BCS IV Drugs, 2022-2035 (USD Billion)
Figure 15.8 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035
Figure 15.9 Bioavailability Enhancement Services Market for Lipid-Based Approaches, 2022-2035 (USD Billion)
Figure 15.10 Bioavailability Enhancement Services Market for Size Reduction Approaches, 2022-2035 (USD Billion)
Figure 15.11 Bioavailability Enhancement Services Market for Solid Dispersion Approaches, 2022-2035 (USD Billion)
Figure 15.12 Bioavailability Enhancement Services Market for Other Approaches, 2022-2035 (USD Billion)
Figure 15.13 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035
Figure 15.14 Bioavailability Enhancement Services Market for Liquids, 2022-2035 (USD Billion)
Figure 15.15 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Billion)
Figure 15.16 Bioavailability Enhancement Services Market for Semi-Solids, 2022-2035 (USD Billion)
Figure 15.17 Bioavailability Enhancement Services Market for Fine Particles / Powders, 2022-2035 (USD Billion)
Figure 15.18 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035
Figure 15.19 Bioavailability Enhancement Services Market in North America, 2022-2035 (USD Billion)
Figure 15.20 Bioavailability Enhancement Services Market in Europe, 2022-2035 (USD Billion)
Figure 15.21 Bioavailability Enhancement Services Market in Asia, 2022-2035 (USD Billion)
Figure 15.22 Bioavailability Enhancement Services Market in Latin America, 2022-2035 (USD Billion)
Figure 15.23 Bioavailability Enhancement Services Market in Middle East and North Africa, 2022-2035 (USD Billion)
Figure 15.24 Bioavailability Enhancement Services Market in Rest of the World, 2022-2035 (USD Billion)
Figure 15.25 Bioavailability Enhancement Services Market: Conservative, Base and Optimistic Scenarios, 2022, 2027 and 2035 (USD Billion)
Figure 16.1 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Service Providers
Figure 16.2 Concluding Remarks: Overall Market Landscape of Bioavailability Enhancement Technologies
Figure 16.3 Concluding Remarks: Partnerships and Collaborations
Figure 16.4 Concluding Remarks: Publication Analysis
Figure 16.5 Concluding Remarks: Patent Analysis
Figure 16.6 Concluding Remarks: Clinical Trial Analysis
Figure 16.7 Concluding Remarks: Demand Analysis
Figure 16.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 16.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

List of Tables

Table 4.1 List of Bioavailability Enhancement Service Providers
Table 4.2 Bioavailability Enhancement Service Providers: Information on BioavailabilityEnhancement Principle
Table 4.3 Bioavailability Enhancement Service Providers: Information on BioavailabilityEnhancement Approach
Table 4.4 Bioavailability Enhancement Service Providers: Information on Solid DispersionApproaches 
Table 4.5 Bioavailability Enhancement Service Providers: Information on Size ReductionApproaches 
Table 4.6 Bioavailability Enhancement Service Providers: Information on Lipid-BasedApproaches 
Table 4.7 Bioavailability Enhancement Service Providers: Information on OtherBioavailability Enhancement Approaches 
Table 4.8 Bioavailability Enhancement Service Providers: Information on Dosage Forms
Table 4.9 Bioavailability Enhancement Service Providers: Information on Routes ofAdministration
Table 5.1 List of Bioavailability Enhancement Technology Providers
Table 5.2 Bioavailability Enhancement Technologies: Information on BioavailabilityEnhancement Principles and Bioavailability Enhancement Approaches
Table 5.3 Bioavailability Enhancement Technologies: Information on Type of Molecule
Table 5.4 Bioavailability Enhancement Technologies: Information on Dosage Forms
Table 5.5 Bioavailability Enhancement Technologies: Information on Routes ofAdministration
Table 5.6 Bioavailability Enhancement Technologies: Information on Availability forLicense and Intellectual Property Rights
Table 7.1 List of Companies Profiled
Table 7.2 Adare Pharma Solutions: Company Snapshot
Table 7.3 Adare Pharma Solutions: Recent Developments and Future Outlook
Table 7.4 Ascendia Pharmaceuticals: Company Snapshot
Table 7.5 Ascendia Pharmaceuticals: Recent Developments and Future Outlook
Table 7.6 Catalent: Company Snapshot
Table 7.7 Catalent: Recent Developments and Future Outlook
Table 7.8 Lonza: Company Snapshot
Table 7.9 Lonza: Recent Developments and Future Outlook
Table 7.10 Lubrizol Life Science Health: Company Snapshot
Table 7.11 Lubrizol Life Science Health: Recent Developments and Future Outlook
Table 7.12 Pace Life Sciences: Company Snapshot
Table 7.13 Pace Life Sciences: Recent Developments and Future Outlook
Table 7.14 Quotient Sciences: Company Snapshot
Table 7.15 Quotient Sciences: Recent Developments and Future Outlook
Table 7.16 WuXi STA (A Subsidiary of WuXi AppTec): Company Snapshot
Table 7.17 WuXi STA (A Subsidiary of WuXi AppTec): Recent Developments and FutureOutlook
Table 9.1 Bioavailability Enhancement: List of Partnerships and Collaborations, 2013-2022
Table 9.2 Bioavailability Enhancement Focused Partnerships and Collaborations:Information on Type of Agreement (Region-wise and Geography-wise)
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 11.6 Patent Portfolio: List of Leading Patents (in terms of Highest Relative Valuation)
Table 11.7 Patent Portfolio: List of Leading Patents (in terms of Number of Citations)
Table 12.1 Bioavailability Studies: Regulatory Guidelines and Methodologies
Table 13.1 Technologies based on Lipid-based Approaches: List of Approved Drugs
Table 13.2 Technologies Based on Lipid-based Approaches: Global Competition
Table 13.3 Technologies based on Size Reduction Approaches: List of Approved Drugs
Table 13.4 Technologies Based on Size Reduction Approaches: Global Competition
Table 13.5 Technologies based on Solid Dispersion Approaches: List of Approved Drugs
Table 13.6 Technologies Based on Solid Dispersion Approaches: Global Competition
Table 13.7 Technologies based on Other Approaches: List of Approved Drugs
Table 13.8 Technologies Based on Other Approaches: Global Competition
Table 18.1 Bioavailability Enhancement Service Providers: Distribution by Year of Establishment
Table 18.2 Bioavailability Enhancement Service Providers: Distribution by Company Size
Table 18.3 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Region wise)
Table 18.4 Bioavailability Enhancement Service Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.5 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Principle
Table 18.6 Bioavailability Enhancement Service Providers: Distribution by Bioavailability Enhancement Approach
Table 18.7 Bioavailability Enhancement Service Providers: Distribution by Solid Dispersion Approaches
Table 18.8 Bioavailability Enhancement Service Providers: Distribution by Size Reduction Approaches
Table 18.9 Bioavailability Enhancement Service Providers: Distribution by Lipid-based Approaches
Table 18.10 Bioavailability Enhancement Service Providers: Distribution by Other Bioavailability Enhancement Approaches
Table 18.11 Bioavailability Enhancement Service Providers: Distribution by Dosage Form
Table 18.12 Bioavailability Enhancement Service Providers: Distribution by Route of Administration
Table 18.13 Bioavailability Enhancement Technology Providers: Distribution by Year of Establishment
Table 18.14 Bioavailability Enhancement Technology Providers: Distribution by Company Size
Table 18.15 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Region-wise)
Table 18.16 Bioavailability Enhancement Technology Providers: Distribution by Location of Headquarters (Country-wise)
Table 18.17 Bioavailability Enhancement Technology Providers: Distribution by Company Size and Location of Headquarters
Table 18.18 Leading Players: Distribution by Number of Technologies
Table 18.19 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle
Table 18.20 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach
Table 18.21 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.22 Bioavailability Enhancement Technologies: Distribution by Type of Molecule
Table 18.23 Bioavailability Enhancement Technologies: Distribution by Bioavailability Enhancement Approach and Type of Molecule
Table 18.24 Bioavailability Enhancement Technologies: Distribution by Dosage Form
Table 18.25 Bioavailability Enhancement Technologies: Distribution by Route of Administration
Table 18.26 Bioavailability Enhancement Technologies: Distribution by Availability for License
Table 18.27 Bioavailability Enhancement Technologies: Distribution by Intellectual Property Rights
Table 18.28 Key Insights: Distribution by Company Size and Location of Headquarters
Table 18.29 Key Insights: Distribution by Location of Headquarters and Bioavailability Enhancement Approach
Table 18.30 Key Insights: Distribution by Bioavailability Enhancement Approach and Dosage Form
Table 18.31 Key Insights: Distribution by Company Size and Bioavailability Enhancement Principle
Table 18.32 Key Insights: Distribution by Bioavailability Enhancement Principle and Bioavailability Enhancement Approach
Table 18.33 Catalent: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 18.34 Lonza: Annual Revenues, FY 2017-HI FY 2022 (CHF Billion)
Table 18.35 WuXi STA (A Subsidiary of WuXi AppTec): Annual Revenues, FY 2017- H1 FY 2022 (USD Billion)
Table 18.36 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2013-2022
Table 18.37 Partnerships and Collaborations: Distribution by Type of Partnership
Table 18.38 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 18.39 Partnerships and Collaborations: Distribution by Type of Partner
Table 18.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 18.41 Most Active Players: Distribution by Number of Partnerships
Table 18.42 Partnerships and Collaborations: Distribution by Location of Headquarters (Region-wise)
Table 18.43 Partnerships and Collaborations: Distribution by Location of Headquarters (Country-wise)
Table 18.44 Partnerships and Collaboration: Distribution by Type of Partnership and Location of Partner Headquarters
Table 18.45 Publication Analysis: Cumulative Distribution by Publication Year, 2017-2022
Table 18.46 Publication Analysis: Distribution by Type of Publication
Table 18.47 Publication Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.48 Publication Analysis: Distribution by Year of Publication and Bioavailability Enhancement Approach
Table 18.49 Most Popular Journals: Distribution by Number of Publications
Table 18.50 Most Popular Journals: Distribution by Journal Impact Factor
Table 18.51 Most Popular Publishers: Distribution by Number of Publications
Table 18.52 Most Popular Copyright Holders: Distribution by Number of Publications
Table 18.53 Patent Analysis: Distribution by Type of Patent
Table 18.54 Patent Analysis: Cumulative Distribution by Application Year, Pre-2010-2022
Table 18.55 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2010-2022
Table 18.56 Patent Analysis: Distribution by Year-wise Trend of Filed Patent Applications and Number of Granted Patents, Pre-2010-2022
Table 18.57 Patent Analysis: Distribution by Bioavailability Enhancement Approach
Table 18.58 Patent Analysis: Distribution by Publication Year and Bioavailability Enhancement Approach
Table 18.59 Patent Analysis: Distribution by Location of Patent Jurisdiction (Region-wise)
Table 18.60 Patent Analysis: Distribution by Location of Patent Jurisdiction (Country-wise)
Table 18.61 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, Pre-2010-2022
Table 18.62 Leading Industry Players: Distribution by Number of Patents
Table 18.63 Leading Non-Industry Players: Distribution by Number of Patents
Table 18.64 Leading Patent Assignees: Distribution by Number of Patents
Table 18.65 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Symbols)
Table 18.66 Patent Analysis: Distribution of Patents by Age (pre-2010-2022)
Table 18.67 Bioavailability Enhancement: Patent Valuation
Table 18.68 Leading Patents: Distribution by Number of Citations
Table 18.69 Bioavailability Studies: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 18.70 Bioavailability Studies: Distribution of Enrolled Patient Population by Trial Registration Year
Table 18.71 Bioavailability Studies: Distribution of Trials by Study Design
Table 18.72 Bioavailability Studies: Distribution of Trials by Trial Phase
Table 18.73 Bioavailability Studies: Distribution of Trials by Recruitment Status
Table 18.74 Bioavailability Studies: Distribution of Trials by Type of Sponsor /Collaborator
Table 18.75 Bioavailability Studies: Distribution of Trials by Type of Molecule and Trial Phase
Table 18.76 Leading Industry Players: Distribution by Number of Registered Trials
Table 18.77 Leading Non-Industry Players: Distribution by Number of Registered Trials
Table 18.78 Bioavailability Studies: Geographical Distribution of Trials
Table 18.79 Bioavailability Studies: Geographical Distribution of Enrolled Patient Population
Table 18.80 Global Demand for Bioavailability Enhancement Technologies and Services, 2022-2035 (In Terms of Number of Projects)
Table 18.81 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Drug Class, 2022 and 2035 (In Terms of Number of Projects)
Table 18.82 Demand for Bioavailability Enhancement Technologies and Services: Distribution by BCS Classification, 2022 and 2035 (In Terms of Number of Projects)
Table 18.83 Demand for Bioavailability Enhancement Technologies and Services: Distribution by Dosage Form, 2022 and 2035 (In Terms of Number of Projects)
Table 18.84 Global Bioavailability Enhancement Services Market, 2022-2035 (USD Million)
Table 18.85 Bioavailability Enhancement Services Market: Distribution by Drug Class, 2022 and 2035 (USD Million)
Table 18.86 Bioavailability Enhancement Services Market for New Drug Approvals, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.87 Bioavailability Enhancement Services Market for Generics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.88 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by BCS Classification, 2022 and 2035 (USD Million)
Table 18.89 Bioavailability Enhancement Services Market for BCS II Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.90 Bioavailability Enhancement Services Market for BCS IV Drugs, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.91 Bioavailability Enhancement Services Market, 2022 and 2035: Distribution by Bioavailability Enhancement Approach, 2022 and 2035 (USD Million)
Table 18.92 Bioavailability Enhancement Services Market for Lipid Based Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.93 Bioavailability Enhancement Services Market for Solid Dispersion Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.94 Bioavailability Enhancement Services Market for Size Reduction Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.95 Bioavailability Enhancement Services Market for Other Bioavailability Enhancement Approaches, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.96 Bioavailability Enhancement Services Market: Distribution by Dosage Form, 2022 and 2035 (USD Million)
Table 18.97 Bioavailability Enhancement Services Market for Liquids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.98 Bioavailability Enhancement Services Market for Solids, 2022-2035 (USD Million)
Table 18.99 Bioavailability Enhancement Services Market for Semi-Solids, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.100 Bioavailability Enhancement Services Market for Fine Particles / Powders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.101 Bioavailability Enhancement Services Market: Distribution by Key Geographies, 2022 and 2035 (USD Million)
Table 18.102 Bioavailability Enhancement Services Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.103 Bioavailability Enhancement Services Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.104 Bioavailability Enhancement Services Market in Asia, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.105 Bioavailability Enhancement Services Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.106 Bioavailability Enhancement Services Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)
Table 18.107 Bioavailability Enhancement Services Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report:

  1. AbbVie Contract Manufacturing
  2. ABITEC
  3. Absorption Systems
  4. Accu-Break Pharmaceuticals
  5. Aché Laboratórios Farmacêuticos
  6. Acorda Therapeutics
  7. Actavis
  8. Adare Pharma Solutions
  9. Admas Pharmaceuticals
  10. ADYA
  11. Aegis Therapeutics
  12. Aeon Respire
  13. Aerami Therapeutics
  14. Agere Pharmaceuticals
  15. Agios Pharmaceuticals 
  16. Aizant Drug Research Solutions
  17. Ajinomoto Bio-Pharma Services
  18. Alcami
  19. Alembic Pharmaceuticals
  20. Alexion Pharmaceuticals
  21. Alimera Sciences
  22. Alkermes
  23. Allergan
  24. Altasciences
  25. Althea Technologies
  26. Altus Drug Development
  27. Amador Bioscience
  28. Amatsigroup
  29. AMRI
  30. APONTIS PHARMA
  31. Applied Manufacturing Science (AMS)
  32. Aptuit
  33. Aragen Life Sciences (Formerly GVK Bio)
  34. Arbro Pharmaceuticals
  35. Arcinova
  36. Ardena
  37. Ascendia Pharmaceuticals
  38. Ascentage Pharma
  39. Ash Stevens
  40. Ashland
  41. Astex Pharmaceuticals
  42. Aurigene Discovery Technologies
  43. Avista Pharma Solutions
  44. Axsome Therapeutics
  45. BASF
  46. Bend Research
  47. Betta Pharmaceuticals
  48. BiGEN
  49. Bio-Concept Laboratories
  50. BioConnection
  51. BioCorRx
  52. BioDuro-Sundia
  53. BioGeneration Ventures (BGV)
  54. Biolingus
  55. Bionpharma
  56. Bioqube Ventures
  57. Biosidus
  58. BIOTTS
  59. Bristol Myers Squibb
  60. Calvert Laboratories
  61. Cambrex
  62. Camurus
  63. Capsugel
  64. Cara Therapeutics
  65. Caraway Therapeutics
  66. Catalent
  67. CD Formulation
  68. ChemConnection
  69. CMC Pharmaceuticals
  70. Co-Formulate
  71. Colorcon
  72. Comera LIFE SCIENCES
  73. COREALIS Pharma
  74. CoreRx
  75. Coripharma
  76. Creative Biolabs
  77. CritiTech Particle Engineering Solutions
  78. Crystal Pharmatech
  79. Crystallics
  80. CrystecPharma
  81. Curia (Formerly AMRI)
  82. CuriRx
  83. Curis
  84. Cyclolab
  85. Dalton Pharma Services 
  86. Dana Farber Cancer Institute
  87. Dauntless Pharmaceuticals
  88. DisperSol Technologies
  89. Dizal Pharmaceutical
  90. Dolomite Microfluidics
  91. Drug Delivery Experts (Acquired by Pace Life Sciences)
  92. DSM Nutritional Products
  93. Eagle Pharmaceuticals
  94. Element Materials Technology
  95. Emmerson Resources
  96. Ennaid Therapeutics
  97. Enteris BioPharma
  98. EPFL
  99. Epigeneron
  100. Equinox Science (Acquired by Betta Pharmaceuticals)
  101. ESSA PHARMA
  102. Eurofarma
  103. Eurofins CDMO
  104. Evonik Health Care
  105. Evotec
  106. ExCellThera
  107. Excivion
  108. Exelead
  109. ExxPharma Therapeutics
  110. EyePoint Pharmaceuticals
  111. Federal Equipment
  112. Ferring Pharmaceuticals
  113. Flexion Therapeutics
  114. Forbion
  115. Forest Laboratories
  116. Formac Pharmaceuticals
  117. Formex
  118. Formulex Pharma Innovations (Formerly SoluBest)
  119. Foster Delivery Science
  120. Frazier Healthcare Partners
  121. Fudan University
  122. Fuji Chemical Industries
  123. Gattefossé
  124. GB Sciences
  125. Gen-Plus
  126. Glatt
  127. Glenmark Pharmaceuticals
  128. GP Pharm
  129. Halo Pharmaceutical (Acquired by Cambrex)
  130. Harvard University
  131. Hemmo Pharmaceuticals
  132. Hofseth BioCare (HBC)
  133. Honeywell
  134. Hovione
  135. Hubei Yuyang Pharmaceutical (Acquired by Proton)
  136. IACTA Pharmaceuticals
  137. iCeutica (Acquired by Iroko Pharmaceuticals)
  138. Icon Bioscience (Acquired by pSivida)
  139. Iconovo
  140. Idifarma
  141. Nutrition & Biosciences (A subsidiary of IFF)
  142. I-Mab
  143. Impact Therapeutics
  144. Inflexion
  145. InfraRed Integrated Systems (Irisys)
  146. Inspira Pharmaceuticals
  147. Instillo Group
  148. Intas Pharmaceuticals
  149. Interpublic (IPG)
  150. iX Syrinx (A subsidiary of iX Biopharma)
  151. Janssen Pharmaceutica
  152. Jetpharma
  153. Ji Xing Pharmaceuticals
  154. Jina Pharmaceuticals
  155. JLL Partners
  156. Johns Hopkins University
  157. J-Star Research
  158. Juniper Pharmaceuticals
  159. KC Pharmaceuticals (Acquired by Kangen Pharmaceuticals)
  160. Kuecept
  161. Kuraray
  162. LakePharma
  163. Larodan
  164. LATITUDE Pharmaceuticals
  165. Leonard Green & Partners
  166. leon-nanodrugs
  167. Lexaria Bioscience
  168. Ligand Pharmaceuticals
  169. Lipomize
  170. Lonza
  171. Losan Pharma
  172. Lubrizol Life Science Health
  173. LYOCONTRACT
  174. Marinus Pharmaceuticals
  175. Massachusetts Institute of Technology
  176. Mayne Pharma
  177. Merck Millipore
  178. Merrion Pharmaceuticals
  179. Metrics Contract Services
  180. MGB Biopharma
  181. Micro-Macinazione
  182. Micro-Sphere
  183. Midas Pharma
  184. MIKA Pharma
  185. Moderna
  186. Monash University
  187. MRM Health
  188. Nanocopoeia
  189. Nanomaterials
  190. NanoMaterials Technology (NMT)
  191. Nanomerics
  192. Natco Pharma
  193. Nemus Bioscience
  194. NETZSCH Premier Technologies
  195. NeutriSci International
  196. New York Center for Nanomedicine Research
  197. Nextar Chempharma Solutions
  198. Nicox
  199. NLS Pharmaceutics
  200. Nordic Bioscience
  201. Novan
  202. Novo Nordisk
  203. Nuance Pharma
  204. Nuformix Technologies
  205. OcuMension Therapeutics
  206. Okklo Life Sciences
  207. Opiant Pharmaceuticals
  208. Orbis Biosciences
  209. Oryn Therapeutics
  210. Oxilio
  211. Pace Life Sciences
  212. Pacira BioSciences
  213. Particle Sciences
  214. Patheon
  215. PCI Pharma Services
  216. Peak Proteins
  217. Pensatech Pharma
  218. Permira
  219. Pfizer
  220. Pharmaceutical Manufacturing Research Services (PMRS)
  221. Pharmaceutical Product Development
  222. Pharmaceutics International
  223. Pharmaron
  224. PharmaSol
  225. Pharmatek
  226. Pharmaterials
  227. Pharmavize
  228. Phasex
  229. Phenom Pharmaceuticals (Acquired by Thermo Fisher Scientific)
  230. Phosphorex
  231. Piramal Pharma Solutions
  232. PixarBio
  233. Porton Pharma Solutions
  234. PowderSize
  235. ProJect Pharmaceutics
  236. ProMed Pharma
  237. PSC Biotech
  238. Pulmatrix
  239. QDevelopment
  240. QS Pharma
  241. Quay Pharma (A subsidiary of SGS)
  242. Quotient Sciences
  243. RenaSci (Acquired by Sygnature Discovery)
  244. Rhythm Pharmaceuticals
  245. Rottendorf Pharma
  246. Samyang Biopharmaceuticals
  247. SARA Pharm Solutions
  248. Scripps Research
  249. SEPS Pharma
  250. Serán Bioscience
  251. Sever Pharma Solutions (Formerly Foster Delivery Science)
  252. SGS
  253. Sichuan University
  254. Siegfried Holding
  255. SignalRx Pharmaceuticals
  256. Singota Solutions
  257. Sino German M&A Service
  258. SiTec PharmaBio
  259. SkyePharma
  260. SocietalTM CDMO (Formerly Recro)
  261. Sofpromed
  262. SolMic Research
  263. Solvay
  264. Solvias
  265. SRAX
  266. STA Pharmaceutical
  267. Standard Industries
  268. Stanipharm
  269. Sundia
  270. Supernus Pharmaceuticals
  271. Sygnature Discovery
  272. Syntagon
  273. Tapemark
  274. Temasek
  275. Tergus Pharma
  276. The University of Texas
  277. Thermo Fisher Scientific
  278. Thomas H Lee Partners
  279. Univar
  280. University of California
  281. UPM Pharmaceuticals
  282. Upperton Pharma Solutions
  283. Vaccine Manufacturing Innovation Centre (VMIC)
  284. Vectura
  285. Vertex Pharmaceuticals
  286. Vesifact
  287. Virpax Pharmaceuticals
  288. VxP Pharma
  289. Water Street Healthcare Partners
  290. Wolfe Laboratories
  291. W. R. Grace
  292. WuXi AppTec
  293. Xcelience
  294. Xedev
  295. Yale University
  296. Ypsomed
  297. Zerion Pharma

PRICING DETAILS

USD 4,799

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.